title: Recent advances in antimultiple myeloma drug development.
abstract: Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the aberrant proliferation of terminally differentiated plasma B cells with impairment in apoptosis capacity. Particularly, osteolytic bone diseases and renal failure resulting from hyperparaproteinemia and hypercalcemia have been the major serious sequelae that are inextricably linked with MM tumor progression. Despite the introduction of new treatment regimens, problematic neuropathy, thrombocytopenia, drug resistance and high MM relapse rates continue to plague the current therapies. New chemical agents are in development on the basis of understanding several signaling pathways and molecular mechanisms like tumor necrosis factor-α, proteasome, PI3K and MARKs. This review focuses on the most recent patents and clinical trials in the development of new medicine for the treatment of multiple myeloma. Furthermore, the important signaling pathways involved in the proliferation, survival and apoptosis of myeloma cells will be discussed.
authors.affiliation: Department of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, School of Pharmacy & Drug Discovery Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA.
authors.forename: Nuozhou
authors.initials: N
authors.lastname: Wang
authors.forename: Patrick
authors.initials: P
authors.lastname: Bartlow
authors.forename: Qin
authors.initials: Q
authors.lastname: Ouyang
authors.forename: Xiang-Qun
authors.initials: XQ
authors.lastname: Xie
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D055808:Drug Discovery; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D010330:Patents as Topic
chemical_list: D000970:Antineoplastic Agents